Significant Ownership of PharmaCyte Biotech, Inc.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for PharmaCyte Biotech, Inc. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Joshua N. Silverman - Joshua N. Silverman, Chief Executive Officer and President
- Manager location
- Las Vegas, NV
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow PharmaCyte Biotech, Inc. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from PharmaCyte Biotech, Inc.
Significant Ownership of PharmaCyte Biotech, Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| QCLS | Q/C TECHNOLOGIES, INC. | Common Stock, par value $0.001 per share | 74% | $28,646,744 | 8,475,368 | PharmaCyte Biotech, Inc. | 14 Nov 2025 | ||
| FEMY | FEMASYS INC | Common Stock, par value $0.0001 per share | 7.9% | $2,762,382 | 4,932,825 | PharmaCyte Biotech, Inc. | 17 Mar 2026 |
Schedules 13D/G Reported by PharmaCyte Biotech, Inc.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.